EMA Authorised: Ivemend (fosaprepitant) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorised Ivemend (fosaprepitant) by Merck Sharp & Dohme B.V. for prevention of chemotherapy-induced vomiting in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Ivemend (fosaprepitant)

Snippet

Status: Authorised. Therapeutic area: Vomiting;Cancer. MAH: Merck Sharp & Dohme B.V.. Decision date: 03/11/2025